<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="Trimethobenzamide" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">livertox</book-id>
    <book-title-group>
      <book-title>LiverTox</book-title>
      <subtitle>Clinical and Research Information on Drug-Induced Liver Injury</subtitle>
    </book-title-group>
    <pub-date date-type="pubr" publication-format="electronic">
      <year>2012</year>
    </pub-date>
    <publisher>
      <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
      <publisher-loc>Bethesda (MD)</publisher-loc>
    </publisher>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">Trimethobenzamide</book-part-id>
      <title-group>
        <title>Trimethobenzamide</title>
      </title-group>
      <pub-history>
        <date date-type="updated">
          <day>3</day>
          <month>9</month>
          <year>2020</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="livertox">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</related-object>
      <related-object link-type="previous-part-link" source-id="livertox" document-id="Trihexyphenidyl" document-type="chapter">Trihexyphenidyl</related-object>
      <related-object link-type="next-part-link" source-id="livertox" document-id="Trimetrexate" document-type="chapter">Trimetrexate</related-object>
    </book-part-meta>
    <body>
      <sec id="Trimethobenzamide.OVERVIEW">
        <title>OVERVIEW</title>
        <sec id="Trimethobenzamide.Introduction" sec-type="pubmed-excerpt">
          <title>Introduction</title>
          <p>Trimethobenzamide is an orally available, antiemetic agent used in the therapy of nausea and vomiting associated with medications and gastrointestinal, viral and other illnesses. Trimethobenzamide has not been linked convincingly to elevations in serum enzymes during therapy and despite widescale use for almost 50 years, it has rarely been linked to instances of clinically apparent liver injury with jaundice.</p>
        </sec>
        <sec id="Trimethobenzamide.Background">
          <title>Background</title>
          <p>Trimethobenzamide (trye meth&#x0201d; oh ben&#x02019; za mide) is a benzamide used to prevent nausea and vomiting. Its mechanism of action is uncertain, but it is believed to act directly on the central chemoreceptor nausea trigger zone of the medulla oblongata of the brain. It has weak antihistaminic activity, but does not appear to act via serotonin or dopamine pathways. Trimethobenzamide was approved for use in the United States in 1974 and is widely used in therapy of nausea, vomiting caused by gastroenteritis, medications and other illnesses. Trimethobenzamide is available as 300 mg capsules in generic forms and under the brand name Tigan. It is also available as a solution for injection (100 mg/mL). Trimethobenzamide used to be available also as suppositories, but this formulation was discontinued due to lack of efficacy. The typical oral dose of trimethobenzamide for in adults is 300 mg three or four times a day as needed, usually for short periods only. Intravenous formulations are used for therapy of postoperative nausea and vomiting. Common side effects include drowsiness, dizziness, headache, fatigue, diarrhea and polyuria. Rare side effects include hypersensitivity reactions, skin rash, disorientation, acute dystonic reactions and extrapyramidal symptoms including muscle spasms of the neck and tongue, opisthotonos, restlessness an akinesia.</p>
        </sec>
        <sec id="Trimethobenzamide.Hepatotoxicity">
          <title>Hepatotoxicity</title>
          <p>Serum aminotransferase elevations during trimethobenzamide therapy are uncommon and rates of such elevations have not been reported in large clinical trials. A single case report of hepatitis and jaundice attributed to trimethobenzamide was published in 1967 that predated availability of tests for hepatitis A, B and C and of modern imaging studies. The latency to onset was approximately 2 weeks and the pattern of injury was mixed. There were no immunoallergic or autoimmune features and recovery was prompt once the medication was stopped. Since that report, there has only been a single mention of possible hepatotoxicity due to trimethobenzamide, a somewhat prolonged case of hepatocellular injury with a cholestatic pattern on liver biopsy despite minimal jaundice. Thus, clinically apparent liver injury from trimethobenzamide must be very rare and is generally mild and self-limited in course.</p>
          <p>Likelihood score: D (possible rare cause of clinically apparent liver injury).</p>
        </sec>
        <sec id="Trimethobenzamide.Mechanism_of_Injury">
          <title>Mechanism of Injury</title>
          <p>Trimethobenzamide is metabolized in the liver but appears to have few drug-drug interactions. The mechanism by which it might cause liver injury is unknown.</p>
        </sec>
        <sec id="Trimethobenzamide.Outcome_and_Management">
          <title>Outcome and Management</title>
          <p>The hepatic injury caused by trimethobenzamide is usually mild and reversible with stopping the medication. Trimethobenzamide has not been linked to cases of acute liver failure, chronic hepatitis or vanishing bile duct syndrome. There is no information about possible cross sensitivity to liver injury with other antiemetics or antihistamines. In view of the many other antiemetics available, rechallenge with trimethobenzamide is not necessary and should be avoided.</p>
          <p>Drug Class: <related-object link-type="booklink" source-id="livertox" document-id="GastrointestinalAgen" document-type="chapter">Gastrointestinal Agents</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="AntiemeticAgents" document-type="chapter">Antiemetics</related-object></p>
        </sec>
      </sec>
      <sec id="Trimethobenzamide.PRODUCT_INFORMATION">
        <title>PRODUCT INFORMATION</title>
        <p>
          <bold>REPRESENTATIVE TRADE NAMES</bold>
        </p>
        <p>Trimethobenzamide &#x02013; Generic, Tigan&#x000ae;</p>
        <p>
          <bold>DRUG CLASS</bold>
        </p>
        <p>Gastrointestinal Agents</p>
        <p>
          <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Trimethobenzamide">COMPLETE LABELING</ext-link>
        </p>
        <p>Product labeling at DailyMed, National Library of Medicine, NIH</p>
      </sec>
      <sec id="Trimethobenzamide.CHEMICAL_FORMULA_AND_S">
        <title>CHEMICAL FORMULA AND STRUCTURE</title>
        <table-wrap id="Trimethobenzamide.Tc" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_Trimethobenzamide.Tc_1_1_1_1" valign="top" align="left" scope="col" rowspan="1" colspan="1">DRUG</th>
                <th id="hd_h_Trimethobenzamide.Tc_1_1_1_2" valign="top" align="left" scope="col" rowspan="1" colspan="1">CAS REGISTRY NO.</th>
                <th id="hd_h_Trimethobenzamide.Tc_1_1_1_3" valign="top" align="left" scope="col" rowspan="1" colspan="1">MOLECULAR FORMULA</th>
                <th id="hd_h_Trimethobenzamide.Tc_1_1_1_4" valign="top" align="left" scope="col" rowspan="1" colspan="1">STRUCTURE</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_Trimethobenzamide.Tc_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Trimethobenzamide</td>
                <td headers="hd_h_Trimethobenzamide.Tc_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pubchem" xlink:href="sid://134973923">138-56-7</ext-link>
                </td>
                <td headers="hd_h_Trimethobenzamide.Tc_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">C21-H28-N2-O5</td>
                <td headers="hd_h_Trimethobenzamide.Tc_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">
                  <related-object link-type="ext-image-back-link" source-id="pubchem" document-id="134973923" document-id-type="sid" document-type="summary" object-id="134973923" object-id-type="sid" object-type="image"/>
                </td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="Trimethobenzamide.ANNOTATED_BIBLIOGRAPHY">
        <title>ANNOTATED BIBLIOGRAPHY</title>
        <p>References updated: 03 September 2020</p>
        <ref-list id="Trimethobenzamide.ANNOTATED_BIBLIOGRAPHY.reflist0">
          <ref id="Trimethobenzamide.REF.zimmerman.1999">
            <mixed-citation publication-type="book">Zimmerman HJ. Antiemetic and prokinetic compounds. Miscellaneous drugs and diagnostic chemicals. In, Zimmerman, HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999: pp. 721.<annotation><p><italic toggle="yes">(Expert review of hepatotoxicity published in 1999 lists trimethobenzamide as having caused a single case of cholestatic liver injury [Borda and Jick: 1987]).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Trimethobenzamide.REF.sharkey.2018">
            <mixed-citation publication-type="book">Sharkey KA, MacNaughton. Antinauseants and antiemetics: Gastrointestinal motility and water flux, emesis, and biliary and pancreatic disease. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman &#x00026; Gilman's the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 934-8.<annotation><p><italic toggle="yes">(Textbook of pharmacology and therapeutics).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Trimethobenzamide.REF.brandman.1960.777">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Brandman</surname>
                  <given-names>O.</given-names>
                </name>
              </person-group>
              <article-title>Clinical evaluation of the effectiveness and safety of trimethobenzamide (tigan).</article-title>
              <source>Gastroenterology</source>
              <year>1960</year>
              <volume>38</volume>
              <fpage>777</fpage>
              <lpage>80</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 50 adults with nausea and vomiting of different causes given a single dose of trimethobenzamide [100 mg orally or intramuscularly], 84% appeared to benefit, and no adverse side effects were observed).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">13803875</pub-id>
            </element-citation>
          </ref>
          <ref id="Trimethobenzamide.REF.wolfson.1962.172">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Wolfson</surname>
                  <given-names>B</given-names>
                </name>
                <name name-style="western">
                  <surname>Torres-Kay</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Foldes</surname>
                  <given-names>FF</given-names>
                </name>
              </person-group>
              <article-title>Investigation of the usefulness of trimethobenzamide (Tigan) for the prevention of postoperative nausea and vomiting.</article-title>
              <source>Anesth Analg</source>
              <year>1962</year>
              <volume>41</volume>
              <fpage>172</fpage>
              <lpage>7</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 870 patients undergoing surgery and anesthesia treated with intramuscular trimethobenzamide vs placebo, "side effects attributable to trimethobenzamide were not observed").</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">14008063</pub-id>
            </element-citation>
          </ref>
          <ref id="Trimethobenzamide.REF.coppolino.1962.326">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Coppolino</surname>
                  <given-names>CA</given-names>
                </name>
                <name name-style="western">
                  <surname>Wallace</surname>
                  <given-names>G</given-names>
                </name>
              </person-group>
              <article-title>Trimethobenzamide antiemetic in immediate postoperative period. Double-blind study in 2,000 cases.</article-title>
              <source>JAMA</source>
              <year>1962</year>
              <volume>180</volume>
              <fpage>326</fpage>
              <lpage>8</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 2000 patients scheduled for elective surgery given intramuscular injections of trimethobenzamide or placebo, nausea was less in the trimethobenzamide treated subjects; no mention of side effects).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">13881235</pub-id>
            </element-citation>
          </ref>
          <ref id="Trimethobenzamide.REF.moertel.1963.116">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Moertel</surname>
                  <given-names>CG</given-names>
                </name>
                <name name-style="western">
                  <surname>Reitemeier</surname>
                  <given-names>RJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Gage</surname>
                  <given-names>RP</given-names>
                </name>
              </person-group>
              <article-title>A controlled clinical evaluation of antiemetic drugs.</article-title>
              <source>JAMA</source>
              <year>1963</year>
              <volume>186</volume>
              <fpage>116</fpage>
              <lpage>8</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 300 patients with cancer receiving fluorouracil who were randomized to receive one of 6 oral antiemetic regimens, the only "significant" side effect was over sedation, which occurred in 8% given prochlorperazine but 0% on trimethobenzamide).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">14056524</pub-id>
            </element-citation>
          </ref>
          <ref id="Trimethobenzamide.REF.nichamin.1964.2">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Nichamin</surname>
                  <given-names>SJ</given-names>
                </name>
              </person-group>
              <article-title>Severe allergic reaction to an antiemetic trimethobenzamide hydrochloride (Tigan).</article-title>
              <source>Harper Hosp Bull</source>
              <year>1964</year>
              <month>Jan-Feb</month>
              <volume>22</volume>
              <fpage>2</fpage>
              <lpage>5</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(4 year old boy developed abdominal pain, arthritis and facial edema a few hours after an intramuscular injection of trimethobenzamide [8% eosinophilia, no liver tests reported], resolving within 3-4 days with epinephrine and diphenhydramine).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">14103491</pub-id>
            </element-citation>
          </ref>
          <ref id="Trimethobenzamide.REF.bardfeld.1966.796">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Bardfeld</surname>
                  <given-names>PA</given-names>
                </name>
              </person-group>
              <article-title>A controlled double-blind study of trimethobenzamide, prochlorperazine, and placebo.</article-title>
              <source>JAMA</source>
              <year>1966</year>
              <volume>196</volume>
              <fpage>796</fpage>
              <lpage>8</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 126 patients with nausea or vomiting of various causes treated with intramuscular injections of trimethobenzamide, prochlorperazine or placebo, drowsiness occurred in 12% and dizziness in 2% of trimethobenzamide treated patients, but no other adverse events were recorded).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">5326281</pub-id>
            </element-citation>
          </ref>
          <ref id="Trimethobenzamide.REF.borda.1967.371">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Borda</surname>
                  <given-names>I</given-names>
                </name>
                <name name-style="western">
                  <surname>Jick</surname>
                  <given-names>H</given-names>
                </name>
              </person-group>
              <article-title>Hepatitis following the administration of trimethobenzamide hydrochloride.</article-title>
              <source>Arch Intern Med</source>
              <year>1967</year>
              <volume>120</volume>
              <fpage>371</fpage>
              <lpage>3</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(50 year old woman with breast cancer receiving irradiation therapy developed jaundice 2 weeks after starting oral trimethobenzamide for prevention of nausea [bilirubin 15.3 mg/dL, ALT 330 U/L, Alk P 14.3 Sigma units], resolving within the following month).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">6038296</pub-id>
            </element-citation>
          </ref>
          <ref id="Trimethobenzamide.REF.hurley.1980.352">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Hurley</surname>
                  <given-names>JD</given-names>
                </name>
                <name name-style="western">
                  <surname>Eshelman</surname>
                  <given-names>FN</given-names>
                </name>
              </person-group>
              <article-title>Trimethobenzamide HCl in the treatment of nausea and vomiting associated with antineoplastic chemotherapy.</article-title>
              <source>J Clin Pharmacol</source>
              <year>1980</year>
              <volume>20</volume>
              <fpage>352</fpage>
              <lpage>6</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 55 patients receiving cancer chemotherapy given intramuscular injections of trimethobenzamide or placebo four times daily for 48 hours, "no side effects attributable to trimethobenzamide were recorded").</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">7400373</pub-id>
            </element-citation>
          </ref>
          <ref id="Trimethobenzamide.REF.chalasani.2008.1924">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Chalasani</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Fontana</surname>
                  <given-names>RJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Bonkovsky</surname>
                  <given-names>HL</given-names>
                </name>
                <name name-style="western">
                  <surname>Watkins</surname>
                  <given-names>PB</given-names>
                </name>
                <name name-style="western">
                  <surname>Davern</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Serrano</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Yang</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>Rochon</surname>
                  <given-names>J</given-names>
                </name>
                <collab>Drug Induced Liver Injury Network (DILIN)</collab>
              </person-group>
              <article-title>Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States.</article-title>
              <source>Gastroenterology</source>
              <year>2008</year>
              <volume>135</volume>
              <fpage>1924</fpage>
              <lpage>34</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 300 cases of drug induced liver disease in the US collected between 2004 and 2008, no cases were attributed to an antiemetic).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">18955056</pub-id>
            </element-citation>
          </ref>
          <ref id="Trimethobenzamide.REF.reuben.2010.2065">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Reuben</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Koch</surname>
                  <given-names>DG</given-names>
                </name>
                <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>WM</given-names>
                </name>
                <collab>Acute Liver Failure Study Group</collab>
              </person-group>
              <article-title>Drug-induced acute liver failure: results of a U.S. multicenter, prospective study.</article-title>
              <source>Hepatology</source>
              <year>2010</year>
              <volume>52</volume>
              <fpage>2065</fpage>
              <lpage>76</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury, but none were attributed to antiemetic agents).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">20949552</pub-id>
            </element-citation>
          </ref>
          <ref id="Trimethobenzamide.REF.ferrajolo.2010.721">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Ferrajolo</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Capuano</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Verhamme</surname>
                  <given-names>KM</given-names>
                </name>
                <name name-style="western">
                  <surname>Schuemie</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Rossi</surname>
                  <given-names>F</given-names>
                </name>
                <name name-style="western">
                  <surname>Stricker</surname>
                  <given-names>BH</given-names>
                </name>
                <name name-style="western">
                  <surname>Sturkenboom</surname>
                  <given-names>MC</given-names>
                </name>
              </person-group>
              <article-title>Drug-induced hepatic injury in children: a case/non-case study of suspected adverse drug reactions in VigiBase.</article-title>
              <source>Br J Clin Pharmacol</source>
              <year>2010</year>
              <volume>70</volume>
              <fpage>721</fpage>
              <lpage>8</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 624,673 adverse event reports in children between 2000 and 2006 in the WHO VigiBase, 1% were hepatic, but no antiemetic was listed among the 41 most commonly implicated agents).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">21039766</pub-id>
            </element-citation>
          </ref>
          <ref id="Trimethobenzamide.REF.bj_rnsson.2013.1419">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Bj&#x000f6;rnsson</surname>
                  <given-names>ES</given-names>
                </name>
                <name name-style="western">
                  <surname>Bergmann</surname>
                  <given-names>OM</given-names>
                </name>
                <name name-style="western">
                  <surname>Bj&#x000f6;rnsson</surname>
                  <given-names>HK</given-names>
                </name>
                <name name-style="western">
                  <surname>Kvaran</surname>
                  <given-names>RB</given-names>
                </name>
                <name name-style="western">
                  <surname>Olafsson</surname>
                  <given-names>S</given-names>
                </name>
              </person-group>
              <article-title>Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland.</article-title>
              <source>Gastroenterology</source>
              <year>2013</year>
              <volume>144</volume>
              <fpage>1419</fpage>
              <lpage>25</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(In a population based study of drug induced liver injury from Iceland, 96 cases were identified over a 2 year period, but none were attributed to antiemetics).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">23419359</pub-id>
            </element-citation>
          </ref>
          <ref id="Trimethobenzamide.REF.hern_ndez.2014.231">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Hern&#x000e1;ndez</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Bessone</surname>
                  <given-names>F</given-names>
                </name>
                <name name-style="western">
                  <surname>S&#x000e1;nchez</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>di Pace</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Brahm</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Zapata</surname>
                  <given-names>R, A</given-names>
                </name>
                <name name-style="western">
                  <surname>Chirino</surname>
                  <given-names>R</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports.</article-title>
              <source>Ann Hepatol</source>
              <year>2014</year>
              <volume>13</volume>
              <fpage>231</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Systematic review of literature of drug induced liver injury in Latin American countries published from 1996 to 2012 identified 176 cases, the most common implicated agents being nimesulide [n=53: 30%], cyproterone [n=18], nitrofurantoin [n=17], antituberculosis drugs [n=13] and flutamide [n=12: 7%]; no antiemetic was listed).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">24552865</pub-id>
            </element-citation>
          </ref>
          <ref id="Trimethobenzamide.REF.chalasani.2015.1340">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Chalasani</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Bonkovsky</surname>
                  <given-names>HL</given-names>
                </name>
                <name name-style="western">
                  <surname>Fontana</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>W</given-names>
                </name>
                <name name-style="western">
                  <surname>Stolz</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Talwalkar</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Reddy</surname>
                  <given-names>KR</given-names>
                </name>
                <etal/>
                <collab>United States Drug Induced Liver Injury Network</collab>
              </person-group>
              <article-title>Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study.</article-title>
              <source>Gastroenterology</source>
              <year>2015</year>
              <volume>148</volume>
              <fpage>1340</fpage>
              <lpage>52.e7</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, none were attributed to trimethobenzamide).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">25754159</pub-id>
            </element-citation>
          </ref>
          <ref id="Trimethobenzamide.REF.siddique.2020.207">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Siddique</surname>
                  <given-names>AS</given-names>
                </name>
                <name name-style="western">
                  <surname>Siddique</surname>
                  <given-names>O</given-names>
                </name>
                <name name-style="western">
                  <surname>Einstein</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Urtasun-Sotil</surname>
                  <given-names>E</given-names>
                </name>
                <name name-style="western">
                  <surname>Ligato</surname>
                  <given-names>S</given-names>
                </name>
              </person-group>
              <article-title>Drug and herbal/dietary supplements-induced liver injury: a tertiary care center experience.</article-title>
              <source>World J Hepatol</source>
              <year>2020</year>
              <volume>12</volume>
              <fpage>207</fpage>
              <lpage>19</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 600 patients who underwent liver biopsy for unexplained rise in serum enzymes over a 5 year period, drug induced liver injury accounted for 38 days, one of which was attributed to trimethobenzamide [bilirubin 15 mg/dL, ALT 630 U/L, Alk P 135 U/L], with a cholestatic hepatitis on biopsy and a prolonged course).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">32547688</pub-id>
            </element-citation>
          </ref>
        </ref-list>
      </sec>
      <sec sec-type="link-group" id="Trimethobenzamide.OTHER_REFERENCE_LINKS">
        <title>OTHER REFERENCE LINKS</title>
        <list list-type="order">
          <list-item>
            <label>1</label>
            <p>
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&#x00026;db=pubmed&#x00026;pubmedfilters=true&#x00026;term=Trimethobenzamide+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)">Recent References on Trimethobenzamide: from PubMed.gov</ext-link>
            </p>
          </list-item>
          <list-item>
            <label>2</label>
            <p>
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?term=Trimethobenzamide">Trials on Trimethobenzamide: from ClinicalTrials.gov</ext-link>
            </p>
          </list-item>
        </list>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
